Abstract
Purpose: Tumor markers that are related to hypoxia, proliferation, DNA damage repair and stem cell-ness, have a prognostic value in advanced stage HNSCC patients when assessed individually. Here we aimed to evaluate and validate this in a multifactorial context and assess interrelation and the combined role of these biological factors in determining chemo-radiotherapy response in HPV-negative advanced HNSCC.Methods: RNA sequencing data of pre-treatment biopsy material from 197 HPV-negative advanced stage HNSCC patients treated with definitive chemoradiotherapy was analyzed. Biological parameter scores were assigned to patient samples using previously generated and described gene expression signatures. Locoregional control rates were used to assess the role of these biological parameters in radiation response and compared to distant metastasis data. Biological factors were ranked according to their clinical impact using bootstrapping methods and multivariate Cox regression analyses that included clinical variables. Multivariate Cox regression analyses comprising all biological variables were used to define their relative role among all factors when combined.Results: Only few biomarker scores correlate with each other, underscoring their independence. The different biological factors do not correlate or cluster, except for the two stem cell markers CD44 and SLC3A2 (r = 0.4, p < 0.001) and acute hypoxia prediction scores which correlated with T-cell infiltration score, CD8+ T cell abundance and proliferation scores (r = 0.52, 0.56, and 0.6, respectively with p < 0.001). Locoregional control association analyses revealed that chronic (Hazard Ratio (HR) = 3.9) and acute hypoxia (HR = 1.9), followed by stem cell-ness (CD44/SLC3A2; HR = 2.2/2.3), were the strongest and most robust determinants of radiation response. Furthermore, multivariable analysis, considering other biological and clinical factors, reveal a significant role for EGFR expression (HR = 2.9, p < 0.05) and T-cell infiltration (CD8+T-cells: HR = 2.2, p < 0.05; CD8+T-cells/Treg: HR = 2.6, p < 0.01) signatures in locoregional control of chemoradiotherapy-treated HNSCC.Conclusion: Tumor acute and chronic hypoxia, stem cell-ness, and CD8+ T-cell parameters are relevant and largely independent biological factors that together contribute to locoregional control. The combined analyses illustrate the additive value of multifactorial analyses and support a role for EGFR expression analysis and immune cell markers in addition to previously validated biomarkers. This external validation underscores the relevance of biological factors in determining chemoradiotherapy outcome in HNSCC.
Highlights
In this study we set out to perform multifactorial analyses to gain understanding of the role and dependence of biological factors that have shown to influence tumor radiation response in preclinical studies and to be associated with radiotherapy response in clinical studies [1, 2]
Based on genetic mutation data, we find a small role for co-occurring CCND1 and CDKN2A mutations in HPV-negative chemo-radiotherapy treated head and neck squamous cell carcinoma (HNSCC) that was not visible in the locoregional control endpoints [36]
Since we aimed to evaluate tumor characteristics with respect to radiation resistance and response, we initially focused on locoregional control outcome values that are mainly determined by the success of the “local” radiotherapy treatment
Summary
In this study we set out to perform multifactorial analyses to gain understanding of the role and dependence of biological factors that have shown to influence tumor radiation response in preclinical studies and to be associated with radiotherapy response in clinical studies [1, 2]. Chemo-radiotherapy is the primary treatment option for advanced head and neck squamous cell carcinoma (HNSCC). Using biological characteristics of the tumors, outcome association studies revealed many potential determinants of prognosis and treatment response in HNSCC [3,4,5,6,7]. Around two third of all HNSCC patients receive radiotherapy as part of their treatment Among these, those with HPV-positive oropharyngeal tumors have a good prognosis, reason to consider them as a new entity in the new TNM staging [11]. HPV-negative HNSCC, in contrast, are characterized by poor prognosis They exhibit frequent amplifications and mutations in proto-oncogenes (EGFR, MYC, HRAS) and in cell cycle genes that drive and support tumor proliferation [14,15,16]. They exhibit frequent amplifications and mutations in proto-oncogenes (EGFR, MYC, HRAS) and in cell cycle genes that drive and support tumor proliferation [14,15,16]. p53 is affected in almost all HPVnegative HNSCC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
